Given the overexpression of somatostatin receptor subtype-2 (SSTR2) in the vast majority of pNETs, we selected the clinically approved SSTR2-targeted radiopharmaceutical 68Ga-DOTA-TOC as a foundation for developing a fluorescent counterpart and produced a first-generation agent that showed SSTR2-mediated targeting in cancer cells and multiple in vivo tumor models [8]. Here, SSTR2 is linked to neoplasm.